Table 3.

Effect of spinal cord B₁R stimulation on tactile allodynia in STZ-diabetic rats

Tactile allodynia (g)
	0 min	5 min	10 min	15 min	30 min	60 min
Control rats
Vehicle	9.7 ± 0.3	9.7 ± 0.3	9.3 ± 0.7	9.7 ± 0.3	9.7 ± 0.3	9.7 ± 0.3
DABK (9.6 nmol, i.t.)	9.7 ± 0.3	9.7 ± 0.3	9.3 ± 0.7	9.7 ± 0.3	9.7 ± 0.3	9.7 ± 0.3
SSR240612 (10 μg, i.t.) + DABK	10.7 ± 0.3	9.7 ± 0.3	9.3 ± 0.7	9.7 ± 0.3	9.7 ± 0.3	9.7 ± 1.3
FLU (1 nmol, i.t.) + DABK	9.7 ± 0.3	9.7 ± 0.3	9.3 ± 0.7	9.7 ± 0.3	9.7 ± 0.3	9.7 ± 0.3
Mino (10 mg/kg, i.p.) + DABK	9.7 ± 0.3	9.7 ± 0.3	9.3 ± 0.7	9.7 ± 0.3	9.7 ± 0.3	9.7 ± 0.3
Tactile allodynia (g)
	0 min	5 min	10 min	15 min	30 min	60 min
STZ-treated rats
Vehicle	6.3 ± 0.3***	6.0 ± 0.5***	6.3 ± 0.3***	6.3 ± 0.3***	6.3 ± 0.3***	6.0 ± 0.5***
DABK (9.6 nmol, i.t.)	6.0 ± 0.5***	5.3 ± 0.4***	4.3 ± 0.3++ ***	5.3 ± 0.4***	6.0 ± 0.0***	5.7 ± 0.3***
SSR240612 (10 μg, i.t.) + DABK	9.3 ± 0.3+++	9.3 ± 0.0+++	9.3 ± 0.0+++	9.3 ± 0.3+++	9.7 ± 0.3+++	9.3 ± 0.0+++
FLU (1 nmol, i.t.) + DABK	9.7 ± 0.3+++	9.7 ± 0.3+++	9.7 ± 0.3+++	9.7 ± 0.3+++	9.3 ± 0.4+++	9.3 ± 0.4+++
Mino (10 mg/kg, i.p.) + DABK	9.7 ± 0.3+++	9.0 ± 0.4+++	9.3 ± 0.4+++	9.3 ± 0.4+++	8.7 ± 0.4+++	9.3 ± 0.4+++

Time-course effect of a single intrathecal (i.t.) injection of the B₁R agonist, des-Arg⁹-BK (DABK, 9.6 nmol), on the paw withdrawal threshold to tactile stimulation (g) in control and 4-day STZ-diabetic rats pre-treated, 3 h earlier, with either B₁R antagonist (SSR240612), microglia inhibitors (minocycline, fluorocitrate) or vehicle. Data represent the mean ± S.E.M. of 4 to 12 rats in each group. Statistical comparison to vehicle in control (*) and STZ-treated rats (⁺) is indicated by ⁺⁺P < 0.01; *** ⁺⁺⁺P < 0.001